Corneal correction for presbyopes

Article

Ner and intermediate vision improvement with a corneal impant

"For a corneal correction of presbyopia to provide a broad depth of focus is exciting news for refractive surgery," according to Dr Vance Thompson, Sioux Falls, South Dakota, USA, speaking of his experiences using the KAMRA inlay (AcuFocus, Irvine, California, USA) at this year's meeting of the American Society of Cataract and Refractive Surgeons (ASCRS). During the same session several doctors revealed their findings using the KAMRA inlay, including an analysis of task performance after implantation, improvements to near vision in emmetropic presbyopic patients, as well as results of simultaneous implantation of the inlay with LASIK.

Quality of life

Dr Thompson examined the task performance of his patients post-implantation. He enrolled 44 patients out of the current IDE total of 507 patients. The patients were between 45 and 60 years of age and ranged from +0.5 to –0.75 D. Dr Thompson said, "In our group of patients their near vision started out blurry but postimplantation there was an improvement to, on average, J2."

Dr Thompson also examined the patients' quality of life after 18 months post-op. He said, "We asked the patients how easy it is for them to perform various everyday tasks at far, intermediate and near distances." Preoperatively, all patients had difficulty reading or viewing a computer screen without glasses, but Dr Thompson said the KAMRA inlay changed that. "After implantation you can see a nice improvement in the intermediate range, looking at the computer screen. You go a little nearer and ask the patients to view a newspaper or a menu and you see a dramatic improvement. Everything is much easier after the implant, even driving at night patients felt comfortable," he added.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
© 2024 MJH Life Sciences

All rights reserved.